OraSure Technologies Inc
NASDAQ:OSUR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
OraSure Technologies Inc
NASDAQ:OSUR
|
US |
|
H
|
Hesai Group
NASDAQ:HSAI
|
CN |
|
S
|
Safe Bulkers Inc
NYSE:SB
|
MC |
|
Cyprium Metals Ltd
ASX:CYM
|
AU |
|
K
|
Kap Industrial Holdings Ltd
JSE:KAP
|
ZA |
|
Magnus Energy Group Ltd
SGX:41S
|
SG |
|
THG PLC
LSE:THG
|
UK |
OraSure Technologies Inc
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. The company is headquartered in Bethlehem, Pennsylvania and currently employs 785 full-time employees. The firm's products include molecular sampling kits for the genome and microbiome services and analytics, rapid diagnostics for infectious disease, and tests for substance abuse. OraSure’s segments include Diagnostics segment and Molecular Collection Systems segment. The Diagnostics business primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices. The Molecular Solutions business consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store biological samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbiome and animal genetics markets.
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. The company is headquartered in Bethlehem, Pennsylvania and currently employs 785 full-time employees. The firm's products include molecular sampling kits for the genome and microbiome services and analytics, rapid diagnostics for infectious disease, and tests for substance abuse. OraSure’s segments include Diagnostics segment and Molecular Collection Systems segment. The Diagnostics business primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices. The Molecular Solutions business consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store biological samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbiome and animal genetics markets.
Revenue: Q4 revenue was $26.8 million, with core revenue at $26.7 million, coming in above the midpoint of guidance.
Margins: Gross margin improved to 41% from 36.2% in the prior year quarter, with further improvements expected as volume increases.
Product Pipeline: Two major product launches are planned for mid-2026: a rapid molecular self-test for chlamydia/gonorrhea and the Colli-Pee at-home urine collection device, both submitted to the FDA in December.
International Growth: Signs of stabilization in key international markets, especially in Africa, with new framework agreements and nearshoring initiatives expected to contribute to revenue in 2026.
Outlook & Guidance: Q1 2026 revenue guided to $26–29 million, with gross margin in the low 40% range and sequential margin improvement expected.
R&D Spending: R&D expenses are expected to decrease in 2026 as clinical trials related to the pipeline wind down.
Shareholder Returns: $15 million returned to shareholders in 2025 through share repurchases.
